October 2020 - SIRIC ILIAD Nantes Angers - Integrated Cancer Research Site

On 22 October 2020 in Brussels, the COST (COoperation in Science and Technology) project dedicated to the development of alpha therapy using astatine-211 was initiated at European level. Under [...]

By SIRIC ILIAD

In Announcements, Patients and the general public, Programme 1 - ThARGET, Programme 2 - PISTER, Programme 3 - ReWork-QoL

Posted 12 October 2020

SIRIC ILIAD shares the progress of its research with its partners

The SIRIC ILIAD Partners and Patient Representatives Committee met on 11 September to present its mid-term review. On 11 September 2020, the third meeting of the SIRIC Partners’ Committee [...]

By SIRIC ILIAD

In Clinical Trails, Programme 1 - ThARGET

Posted 10 October 2020

Clinical trial: FICTIoN Cohort

FICTIoN Cohort: Radiomic analyses of 18FDG PET and correlation with histology Type of study: Single-centre study Pathology: Triple-negative breast cancer, operated on or undergoing adjuvant [...]

By SIRIC ILIAD

In Announcements, Programme 1 - ThARGET

Posted 8 October 2020

Telix – SIRIC ILIAD Collaboration: TLX102 multiple myeloma treatment receives FDA orphan drug designation

The TLX102 treatment, resulting from the collaboration between Telix Pharmaceuticals (Australia), Osaka University (Japan) and the SIRIC ILIAD nuclear medicine teams (CRCINA and Cyclotron [...]

Kick-off of the NOAR network, the COST project dedicated to the development of alpha therapy

SIRIC ILIAD shares the progress of its research with its partners

Clinical trial: FICTIoN Cohort

Telix – SIRIC ILIAD Collaboration: TLX102 multiple myeloma treatment receives FDA orphan drug designation